JP5587950B2 - 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 - Google Patents

臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 Download PDF

Info

Publication number
JP5587950B2
JP5587950B2 JP2012145847A JP2012145847A JP5587950B2 JP 5587950 B2 JP5587950 B2 JP 5587950B2 JP 2012145847 A JP2012145847 A JP 2012145847A JP 2012145847 A JP2012145847 A JP 2012145847A JP 5587950 B2 JP5587950 B2 JP 5587950B2
Authority
JP
Japan
Prior art keywords
parapoxvirus
fibrosis
cells
liver
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2012145847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012214492A (ja
Inventor
クラウディア・ヒルト−ディートリッヒ
トビアス・シュラップ
アンゲラ・ジークリング
アンドレアス・クノール
オラフ・ヴェーバー
グトルン・タイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of JP2012214492A publication Critical patent/JP2012214492A/ja
Application granted granted Critical
Publication of JP5587950B2 publication Critical patent/JP5587950B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012145847A 2000-07-11 2012-06-28 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 Expired - Lifetime JP5587950B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10033581.0 2000-07-11
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
DE10122233.5 2001-05-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002508473A Division JP5106736B2 (ja) 2000-07-11 2001-07-11 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014124405A Division JP5950964B2 (ja) 2000-07-11 2014-06-17 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Publications (2)

Publication Number Publication Date
JP2012214492A JP2012214492A (ja) 2012-11-08
JP5587950B2 true JP5587950B2 (ja) 2014-09-10

Family

ID=7648485

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012145847A Expired - Lifetime JP5587950B2 (ja) 2000-07-11 2012-06-28 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
JP2014124405A Expired - Lifetime JP5950964B2 (ja) 2000-07-11 2014-06-17 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014124405A Expired - Lifetime JP5950964B2 (ja) 2000-07-11 2014-06-17 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Country Status (14)

Country Link
JP (2) JP5587950B2 (ko)
KR (1) KR100845643B1 (ko)
CN (1) CN101444539B (ko)
AT (1) ATE445413T1 (ko)
BR (1) BRPI0112411B8 (ko)
DE (2) DE10122233A1 (ko)
DK (1) DK1303302T3 (ko)
DO (1) DOP2001000210A (ko)
EC (1) ECSP034420A (ko)
ES (1) ES2332355T3 (ko)
PE (1) PE20020218A1 (ko)
PT (1) PT1303302E (ko)
SV (1) SV2002000527A (ko)
ZA (1) ZA200300276B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
US11077157B2 (en) 2016-02-16 2021-08-03 Osaka University Medicinal composition for treating fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100302994B1 (ko) * 1996-04-15 2001-11-30 안톤 마이어 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용

Also Published As

Publication number Publication date
CN101444539A (zh) 2009-06-03
ZA200300276B (en) 2004-04-13
DE50115181D1 (de) 2009-11-26
BR0112411A (pt) 2003-05-27
CN101444539B (zh) 2016-07-06
ECSP034420A (es) 2003-03-10
PE20020218A1 (es) 2002-05-19
KR100845643B1 (ko) 2008-07-10
BRPI0112411B8 (pt) 2021-05-25
SV2002000527A (es) 2002-10-24
DK1303302T3 (da) 2010-02-08
JP2014196329A (ja) 2014-10-16
DE10122233A1 (de) 2002-01-24
DOP2001000210A (es) 2002-12-15
ES2332355T3 (es) 2010-02-03
ATE445413T1 (de) 2009-10-15
KR20030019562A (ko) 2003-03-06
JP5950964B2 (ja) 2016-07-13
JP2012214492A (ja) 2012-11-08
PT1303302E (pt) 2009-11-11
BRPI0112411B1 (pt) 2018-02-27

Similar Documents

Publication Publication Date Title
EP2510088B1 (en) Oncolytic rhabdovirus
CN102631666A (zh) 一种预防和控制人乳头瘤病毒感染的生物制剂的制备方法
EA034195B1 (ru) Штаммы бактериофага, способные вызывать литическую инфекцию адгезивно-инвазивного штамма escherichia coli, и их применение
JP5106736B2 (ja) 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
JP5950964B2 (ja) 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
Tonew et al. Replication and persistence of coxsackieviruses B3 in human fibroblasts
JP6875745B2 (ja) 線維化を治療するための医薬組成物
TWI755725B (zh) 桑黃菌絲體生物活性物質及其用於製備抗腸病毒７１型的抗病毒組成物之用途
US20080305129A1 (en) Highly Attenuated Pox Virus Strains, Method for the Production Thereof and the Use Thereof as Paramunity Inducers or For Producing Vector Vaccines
Weissenbacher et al. Sensitivity of human conjunctival tissue cultures to adenovirus 8, herpes simplex and vaccinia viruses. Induction of resistance by an interferon inducer
CN101082042A (zh) 人工改造的缺陷型人3型腺病毒的应用
Yang et al. Type I interferons triggered through the TLR3-TRIF pathway control
Kriek The oncolytic properties of two newcastle disease virus strains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140724

R150 Certificate of patent or registration of utility model

Ref document number: 5587950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term